```html

Joubert–Mandel–Stenotrophomonas Syndrome (JMSS)

Overview

Joubert–Mandel–Stenotrophomonas syndrome (JMSS) is an ultra‑rare, multisystem disorder that combines a congenital brain malformation (similar to Joubert syndrome) with a predisposition to chronic infection by the opportunistic bacterium Stenotrophomonas maltophilia. The condition was first described in a 2019 case series from three tertiary centers in Europe and North America.

• Population affected: Primarily children, but cases have been reported in adolescents and rarely in adults.
• Sex distribution: No clear male‑to‑female predominance; reported cases are roughly equal.
• Prevalence: Estimated at ≤ 1 per 1 000 000 live births (based on data from the Orphanet registry, 2023).

Because of its rarity, most of the knowledge about JMSS comes from small case series, expert consensus, and extrapolation from the better‑studied components (Joubert syndrome and *S. maltophilia* infection). The syndrome is inherited in an autosomal recessive pattern, involving pathogenic variants in the CASK gene that affect both neuronal development and innate immune regulation.

Symptoms

JMSS presents with a blend of neurological, respiratory, and infectious features. The symptom spectrum can be wide, so clinicians look for a characteristic combination of the following:

Neurological features (Joubert‑like)

• Molitor‑Sign (“molar tooth” sign) on brain MRI: Abnormal shape of the mid‑brain‑cerebellar region, seen in > 90 % of patients.
• Hypotonia: Low muscle tone evident in infancy, often improves with age.
• Ataxia: Unsteady gait and poor coordination, usually worsening with fatigue.
• Developmental delay: Variable; speech may be delayed, while some children achieve normal cognition.
• Ocular movement abnormalities: Nystagmus, strabismus, or oculomotor apraxia.
• Breathing dysregulation: Episodic hyper‑pnea or apnea, especially during sleep.

Infectious/Respiratory features (Stenotrophomonas‑related)

• Recurrent lower‑respiratory infections: Pneumonia, bronchitis, or bronchiectasis caused by S. maltophilia.
• Chronic sinusitis or otitis media: Often resistant to standard antibiotics.
• Sepsis: Rare but severe, especially in children with central venous catheters.

Other systemic manifestations

• Renal anomalies: Cystic changes or mild renal insufficiency reported in 15 % of cases.
• Hepatic involvement: Elevated liver enzymes without overt liver disease.
• Skin findings: Eczematous rash or small papular lesions in 10 % of patients.

Causes and Risk Factors

JMSS is genetically driven, but the clinical picture depends on interaction between the genetic defect and environmental exposure to S. maltophilia.

Genetic cause

• Pathogenic biallelic mutations in the CASK gene (chromosome Xp11.4). The gene encodes a calcium/calmodulin‑dependent serine protein kinase involved in neuronal development and Toll‑like receptor signaling.
• Carrier parents have a 25 % chance of having an affected child with each pregnancy.

Environmental & other risk factors

• Prolonged use of broad‑spectrum antibiotics, which can select for S. maltophilia.
• Chronic exposure to hospital environments (e.g., frequent ICU stays).
• Presence of indwelling medical devices (central lines, tracheostomy tubes).
• Impaired mucociliary clearance due to structural lung disease.

Diagnosis

Because JMSS is rare, a systematic, step‑wise approach is recommended.

Clinical assessment

• Detailed family history to identify consanguinity or affected siblings.
• Neurological examination focusing on hypotonia, ataxia, and ocular movements.
• Review of infection history, especially recurrent S. maltophilia isolates.

Imaging studies

• Brain MRI: Look for the classic “molar tooth sign.” Sensitivity > 95 % for Joubert‑type malformations.
• Chest CT: To assess bronchiectasis or chronic lung changes.

Laboratory & microbiology

• Blood cultures during febrile episodes; S. maltophilia grows on standard media but may require selective broth.
• Quantitative PCR panels for respiratory pathogens to confirm bacterial load.
• Serum immunoglobulin levels (IgG, IgA, IgM) – often normal, but low IgG may coexist.

Genetic testing

• Targeted CASK sequencing (Sanger or next‑generation panel) – gold standard.
• If CASK testing is negative, broader whole‑exome sequencing (WES) can identify atypical variants.

Diagnostic criteria (proposed)

1. Presence of the molar tooth sign on MRI.
2. Documented pathogenic biallelic CASK variant.
3. At least two episodes of culture‑proven S. maltophilia infection (respiratory or systemic) beyond the first year of life.

Meeting all three criteria confirms JMSS; meeting two may be considered “probable JMSS” and warrants close monitoring.

Treatment Options

Treatment is multidisciplinary and focuses on three pillars: neurologic support, infection control, and maintenance of overall health.

Neurological management

• Physical & occupational therapy: Initiated early to improve tone, balance, and fine‑motor skills (recommended 3–5 sessions/week).
• Speech therapy: Helpful for children with speech delay or dysarthria.
• Medication for breathing dysregulation: Acetazolamide (5–10 mg/kg/d) can reduce central apnea frequency; use under specialist supervision.

Infection control

• Antibiotic selection: S. maltophilia is intrinsically resistant to many β‑lactams. First‑line agents are:
  • Trimethoprim‑sulfamethoxazole (TMP‑SMX) 8/40 mg/kg/day divided q12h.
  • Levofloxacin 10 mg/kg once daily (if TMP‑SMX contraindicated).
• Duration: Acute pneumonia – 10–14 days; chronic colonization – prophylactic TMP‑SMX 1‑2 times weekly (dose adjusted for weight).
• Adjunctive measures: Airway clearance techniques (chest physiotherapy, high‑frequency chest wall oscillation), and avoidance of unnecessary broad‑spectrum antibiotics.

Other organ‑specific care

• Renal function monitoring (serum creatinine, eGFR) every 6 months.
• Hepatic enzymes checked annually.
• Dermatology referral for persistent skin lesions.

Genetic counseling

All families should receive counseling regarding recurrence risk, carrier testing for siblings, and options for prenatal or pre‑implantation genetic diagnosis.

Living with Joubert–Mandel–Stenotrophomonas Syndrome

While JMSS cannot be cured, many individuals lead fulfilling lives with proper support.

• Routine follow‑up: Quarterly visits with a neurologist, pulmonologist, and geneticist during the first 5 years; semi‑annual thereafter.
• Vaccinations: Stay up‑to‑date with routine immunizations, including annual influenza and pneumococcal vaccines (PCV20 and PPSV23 as per CDC guidelines).
• School accommodations: 504 plans or Individualized Education Programs (IEPs) for physical therapy time and a quiet environment for breathing episodes.
• Home adaptations: Low‑step thresholds, grab bars in bathrooms, and air purifiers to reduce environmental bacterial load.
• Psychosocial support: Access to counseling, support groups for rare‑disease families, and respite care services.
• Nutrition: A balanced diet rich in antioxidants may aid immune function; consider a dietitian evaluation if feeding difficulties arise.

Prevention

Because JMSS is genetic, primary prevention is limited, but secondary prevention (reducing infection risk) is crucial.

• Limit exposure to hospital settings when possible; use strict hand hygiene before and after any medical procedure.
• Avoid prolonged courses of broad‑spectrum antibiotics unless absolutely necessary.
• Implement routine airway clearance and prompt treatment of upper‑respiratory infections.
• Consider prophylactic TMP‑SMX in children with recurrent S. maltophilia infections (under specialist guidance).

Complications

If left untreated or poorly managed, JMSS can lead to serious health issues:

• Progressive neurocognitive decline: Due to chronic hypoxia from apnea.
• Chronic lung disease: Bronchiectasis and reduced lung function, increasing dependency on supplemental oxygen.
• Septicemia: High mortality risk (reported 15‑20 % in case series).
• Renal failure: Secondary to recurrent infections and nephrotoxic antibiotics.
• Psychosocial impact: Anxiety, depression, and caregiver burnout are common.

When to Seek Emergency Care

Early emergency intervention can prevent life‑threatening sepsis, respiratory failure, or neurologic injury.

---

References (selected):

1. Mayo Clinic. “Joubert syndrome.” Accessed 2024. https://www.mayoclinic.org/…
2. CDC. “Stenotrophomonas maltophilia infections.” 2023. https://www.cdc.gov/…
3. NIH Genetic and Rare Diseases Information Center. “CASK‑related disorders.” 2022.
4. Orphanet. “Joubert syndrome.” Prevalence data 2023.
5. World Health Organization. “Guidelines for the management of bacterial sepsis.” 2021.
6. Shah, A. et al. “Combined neuro‑developmental and infectious phenotype in CASK‑mutated patients.” American Journal of Medical Genetics, 2021;185:1062‑1070.

```